Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

The pathogenesis of acute myeloid leukemia (AML) involves serial acquisition of mutations controlling several cellular processes, requiring combination therapies affecting key downstream survival nodes in order to treat the disease effectively. The BCL2 selective inhibitor venetoclax has potent anti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Han, Lina, Zhang, Qi, Dail, Monique, Shi, Ce, Cavazos, Antonio, Ruvolo, Vivian R., Zhao, Yang, Kim, Eugene, Rahmani, Mohamed, Mak, Duncan H., Jin, Sha S., Chen, Jun, Phillips, Darren C., Koller, Paul Bottecelli, Jacamo, Rodrigo, Burks, Jared K., DiNardo, Courtney, Daver, Naval, Jabbour, Elias, Wang, Jing, Kantarjian, Hagop M., Andreeff, Michael, Grant, Steven, Leverson, Joel D., Sampath, Deepak, Konopleva, Marina
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2020
Matèries:
Aticle
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049339/
https://ncbi.nlm.nih.gov/pubmed/31123034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.205534
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars